CHORDIA THERAPEUTICS INC

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.chordiatherapeutics.com

Country

Japan

Exchange

Tokyo

Chordia Therapeutics Inc., a biotech company provides research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers..

Its portfolio also includes CTX-177, a small-molecule inhibitor of MALT1, CDK12 inhibitor CTX-439, and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.

Key Stats

52-Week Range

¥66.00¥193.00

Beta3.15

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-20.67

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.